Published in Clin Drug Investig on January 01, 2010
Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study. BMC Neurol (2013) 1.06
Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study. BMC Neurol (2012) 1.02
Relapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate: a US claims database study. PLoS One (2014) 0.96
Patient Preferences for Injectable Treatments for Multiple Sclerosis in the United States: A Discrete-Choice Experiment. Patient (2016) 0.96
Patient perceptions of multiple sclerosis and its treatment. Patient Prefer Adherence (2012) 0.91
Treatment selection and experience in multiple sclerosis: survey of neurologists. Patient Prefer Adherence (2014) 0.89
Adherence to Disease Modifying Drugs among Patients with Multiple Sclerosis in Germany: A Retrospective Cohort Study. PLoS One (2015) 0.87
An observational, retrospective, UK and Ireland audit of patient adherence to subcutaneous interferon beta-1a injections using the RebiSmart(®) injection device. Patient Prefer Adherence (2014) 0.87
Treatment adherence and other patient-reported outcomes as cost determinants in multiple sclerosis: a review of the literature. Patient Prefer Adherence (2014) 0.87
Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group. Neurol Sci (2013) 0.87
A discrete-choice experiment to determine patient preferences for injectable multiple sclerosis treatments in Germany. Ther Adv Neurol Disord (2016) 0.86
Background information on multiple sclerosis patients stopping ongoing immunomodulatory therapy: a multicenter study in a community-based environment. J Neurol (2012) 0.85
A multicenter study of the predictors of adherence to self-injected glatiramer acetate for treatment of relapsing-remitting multiple sclerosis. J Neurol (2010) 0.85
Treatment discontinuation and disease progression with injectable disease-modifying therapies: findings from the north american research committee on multiple sclerosis database. Int J MS Care (2013) 0.84
Evaluation of an electronic diary for improvement of adherence to interferon beta-1b in patients with multiple sclerosis: design and baseline results of an observational cohort study. BMC Neurol (2013) 0.83
Managing treatment fatigue in patients with multiple sclerosis on long-term therapy: the role of multiple sclerosis nurses. Patient Prefer Adherence (2014) 0.83
Long-Term Adherence to IFN Beta-1a Treatment when Using RebiSmart® Device in Patients with Relapsing-Remitting Multiple Sclerosis. PLoS One (2016) 0.81
Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study. Mult Scler (2016) 0.80
Adherence to interferon β-1a therapy using an electronic self-injector in multiple sclerosis: a multicentre, single-arm, observational, phase IV study. BMC Res Notes (2016) 0.80
Therapy satisfaction and adherence in patients with relapsing-remitting multiple sclerosis: the THEPA-MS survey. Ther Adv Neurol Disord (2016) 0.79
The Combined Effect of Nursing Support and Adverse Event Mitigation on Adherence to Interferon Beta-1b Therapy in Early Multiple Sclerosis: The START Study. Int J MS Care (2012) 0.79
Persistence and adherence in multiple sclerosis patients starting glatiramer acetate treatment: assessment of relationship with care received from multiple disciplines. Patient Prefer Adherence (2016) 0.78
Therapy optimization in multiple sclerosis: a prospective observational study of therapy compliance and outcomes. BMC Neurol (2014) 0.78
Management Strategies for Flu-Like Symptoms and Injection-Site Reactions Associated with Peginterferon Beta-1a: Obtaining Recommendations Using the Delphi Technique. Int J MS Care (2016) 0.78
Changes in first-line injectable disease-modifying therapy for multiple sclerosis: predictors of non-adherence, switching, discontinuation, and interruption of drugs. Neurol Sci (2017) 0.77
Adherence and cost in multiple sclerosis patients treated with IM IFN beta-1a: impact of the CARE patient management program. BMC Neurol (2015) 0.77
Immunological mechanism of action and clinical profile of disease-modifying treatments in multiple sclerosis. CNS Drugs (2014) 0.77
Improvement of interferon-beta related skin reactions after diluent halving: first experience of five patients. Patient Prefer Adherence (2012) 0.77
Multiple Sclerosis Therapy With Disease-Modifying Treatments in Germany: The PEARL (ProspEctive phArmacoeconomic cohoRt evaluation) Noninterventional Study Protocol. JMIR Res Protoc (2016) 0.76
Exacerbation history is associated with medication and appointment adherence in MS. J Behav Med (2011) 0.76
Treatment satisfaction, adherence and behavioral assessment in patients de-escalating from natalizumab to interferon β. BMC Neurol (2014) 0.76
The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis. BMC Res Notes (2016) 0.75
Treatment adherence in multiple sclerosis: a survey of Belgian neurologists. Patient Prefer Adherence (2015) 0.75
Enhanced patient support services improve patient persistence with multiple sclerosis treatment. Patient Prefer Adherence (2014) 0.75
Subcutaneous Interferon β-1a Administration by Electronic Auto-injector is Associated with High Adherence in Patients with Relapsing Remitting Multiple Sclerosis in a Real-life Study. Neurol Int (2017) 0.75
Impact of adherence on subcutaneous interferon beta-1a effectiveness administered by Rebismart(®) in patients with multiple sclerosis. Patient Prefer Adherence (2017) 0.75
Psychosocial predictors of patient adherence to disease-modifying therapies for multiple sclerosis. Patient Prefer Adherence (2017) 0.75
Glatiramer acetate treatment persistence - but not adherence - in multiple sclerosis patients is predicted by health-related quality of life and self-efficacy: a prospective web-based patient-centred study (CAIR study). Health Qual Life Outcomes (2017) 0.75
Reasons for discontinuation of subcutaneous interferon β-1a three times a week among patients with multiple sclerosis: a real-world cohort study. BMC Neurol (2017) 0.75
Teriflunomide for the treatment of relapsing-remitting multiple sclerosis: patient preference and adherence. Patient Prefer Adherence (2015) 0.75
Nurses' perspective on approaches to limit flu-like symptoms during interferon therapy for multiple sclerosis. Int J MS Care (2014) 0.75
An evaluation of adherence in patients with multiple sclerosis newly initiating treatment with a self-injectable or an oral disease-modifying drug. Patient Prefer Adherence (2016) 0.75
Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis. Biologics (2016) 0.75
Prognostic factors for long-term outcomes in relapsing-remitting multiple sclerosis. Mult Scler J Exp Transl Clin (2016) 0.75
Assessment of treatment patterns associated with injectable disease-modifying therapy among relapsing-remitting multiple sclerosis patients. Mult Scler J Exp Transl Clin (2017) 0.75
Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis. Clinicoecon Outcomes Res (2017) 0.75
Effect of adherence to the first-generation injectable immunomodulatory drugs on disability accumulation in multiple sclerosis: a longitudinal cohort study. BMJ Open (2017) 0.75
Potassium channel KIR4.1 as an immune target in multiple sclerosis. N Engl J Med (2012) 2.90
Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood (2011) 2.44
Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients. J Neurol Neurosurg Psychiatry (2013) 2.23
Diagnosis and management of calcified carotid artery atheroma: dental perspectives. Oral Surg Oral Med Oral Pathol Oral Radiol (2012) 2.14
L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology (2013) 2.02
PTPN22 deficiency cooperates with the CD45 E613R allele to break tolerance on a non-autoimmune background. J Immunol (2009) 1.79
Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med (2009) 1.63
The IBV Valve trial: a multicenter, randomized, double-blind trial of endobronchial therapy for severe emphysema. J Bronchology Interv Pulmonol (2014) 1.51
The Asthma-COPD Overlap Syndrome: A Common Clinical Problem in the Elderly. J Allergy (Cairo) (2011) 1.49
Unmet substance abuse treatment need, health services utilization, and cost: a population-based emergency department study. Ann Emerg Med (2005) 1.43
Low vitamin D and elevated immunoreactivity against Epstein-Barr virus before first clinical manifestation of multiple sclerosis. J Neurol Neurosurg Psychiatry (2012) 1.41
Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol (2013) 1.30
Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. Mult Scler (2013) 1.22
Positional mapping for amplified DNA sequences on 1q21-q22 in hepatocellular carcinoma indicates candidate genes over-expression. J Hepatol (2003) 1.17
Mitochondrial haplogroup H correlates with ATP levels and age at onset in Huntington disease. J Mol Med (Berl) (2010) 1.13
Functional identification of pathogenic autoantibody responses in patients with multiple sclerosis. Brain (2012) 1.06
Standard and escalating treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Ther Adv Neurol Disord (2011) 1.05
Impact of high-deductible health plans on health care utilization and costs. Health Serv Res (2010) 1.04
Astrocytes are less efficient in the removal of apoptotic lymphocytes than microglia cells: implications for the role of glial cells in the inflamed central nervous system. J Neuropathol Exp Neurol (2002) 1.02
A bibliometric analysis of health economics articles in the economics literature: 1991-2000. Health Econ (2003) 0.99
Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve (2008) 0.97
Genome-wide significant association of ANKRD55 rs6859219 and multiple sclerosis risk. J Med Genet (2013) 0.96
MANBA, CXCR5, SOX8, RPS6KB1 and ZBTB46 are genetic risk loci for multiple sclerosis. Brain (2013) 0.94
Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany. Ther Adv Neurol Disord (2012) 0.93
Technical efficiency in the use of health care resources: a comparison of OECD countries. Health Policy (2004) 0.91
alpha4-Integrin antagonism with natalizumab: effects and adverse effects. J Neurol (2008) 0.90
Allergic and nonallergic delayed infusion reactions during natalizumab therapy. Arch Neurol (2008) 0.90
Glucocorticoid effects on endothelial barrier function in the murine brain endothelial cell line cEND incubated with sera from patients with multiple sclerosis. Mult Scler (2010) 0.89
Plasma osteopontin, hypoxia, and response to radiotherapy in nasopharyngeal cancer. Clin Cancer Res (2008) 0.88
Phagocytotic removal of apoptotic, inflammatory lymphocytes in the central nervous system by microglia and its functional implications. J Neuroimmunol (2002) 0.87
Prostacyclin administration errors in pulmonary arterial hypertension patients admitted to hospitals in the United States: a national survey. J Heart Lung Transplant (2010) 0.87
Closing the case of APOE in multiple sclerosis: no association with disease risk in over 29 000 subjects. J Med Genet (2012) 0.86
The relationship between health and development: health as an economic engine. Tenn Med (2003) 0.86
PGC-1alpha downstream transcription factors NRF-1 and TFAM are genetic modifiers of Huntington disease. Mol Neurodegener (2011) 0.84
How can we improve the translational landscape for a faster cure of type 1 diabetes? J Clin Invest (2009) 0.84
Challenges in designing a national surveillance program for inflammatory bowel disease in the United States. Inflamm Bowel Dis (2014) 0.83
Bronchiolitis obliterans. Clin Rev Allergy Immunol (2003) 0.83
Anti-inflammatory effects of the anticonvulsant drug levetiracetam on electrophysiological properties of astroglia are mediated via TGFβ1 regulation. Br J Pharmacol (2011) 0.82
Differential expression of BDNF mRNA splice variants in mouse brain and immune cells. J Neuroimmunol (2006) 0.82
Rescue therapy with anti-CD20 treatment in neuroimmunologic breakthrough disease. J Neurol (2007) 0.82
Thoracic manifestations of common nonpulmonary malignancies of women. Clin Chest Med (2004) 0.81
Downregulation of transforming growth factor-beta2 facilitates inflammation in the central nervous system by reciprocal astrocyte/microglia interactions. J Neuropathol Exp Neurol (2007) 0.81
Identification of four distinct regions of allelic imbalances on chromosome 1 by the combined comparative genomic hybridization and microsatellite analysis on hepatocellular carcinoma. Mod Pathol (2002) 0.81
Immunomodulation and postpartum relapses in patients with multiple sclerosis. Ther Adv Neurol Disord (2009) 0.80
Plasma exchange therapy for steroid-refractory superimposed relapses in secondary progressive multiple sclerosis. J Neurol (2007) 0.80
1H-magnetic resonance spectroscopy in diffuse and focal cervical cord lesions in multiple sclerosis. Eur Radiol (2013) 0.79
Translational research in neurology and neuroscience 2010: multiple sclerosis. Arch Neurol (2010) 0.79
A newborn with Pierre Robin sequence after preconceptional mitoxantrone exposure of a female with multiple sclerosis. J Neurol Sci (2011) 0.79
Assessment of microRNA-related SNP effects in the 3' untranslated region of the IL22RA2 risk locus in multiple sclerosis. Neurogenetics (2014) 0.79
TennCare--Medicaid managed care in Tennessee in jeopardy. Am J Manag Care (2002) 0.78
SPR1. An early molecular marker for bronchial carcinogenesis. Methods Mol Med (2003) 0.78
Polymorphisms in genes encoding leptin, ghrelin and their receptors in German multiple sclerosis patients. Mol Cell Probes (2011) 0.78
Tennessee's option to expand Medicaid coverage: what are the issues? Tenn Med (2012) 0.78
Functional energetics of CD4+-cellular immunity in monoclonal antibody-associated progressive multifocal leukoencephalopathy in autoimmune disorders. PLoS One (2011) 0.78
African American patients' attitudes toward proactive health behaviors after exposure to direct-to-consumer advertising. J Natl Med Assoc (2010) 0.78
Potentially avoidable pediatric hospitalizations as defined by the Agency for Healthcare Research and Quality: what do they tell us about disparities in child health? Clin Pediatr (Phila) (2007) 0.78
Accessibility of antiretroviral therapy in Ghana: convenience of access. SAHARA J (2012) 0.78
Obstructive sarcoidosis. Clin Rev Allergy Immunol (2003) 0.77
Single-detector helical CT in PET-CT: assessment of image quality. AJR Am J Roentgenol (2004) 0.77
Health as an economic engine: evidence for the importance of health in economic development. J Health Hum Serv Adm (2008) 0.77
Independent replication of STAT3 association with multiple sclerosis risk in a large German case-control sample. Neurogenetics (2011) 0.77
The role of aspirin in colorectal cancer prevention and treatment. Oncology (Williston Park) (2013) 0.77
Natalizumab-associated reversible encephalopathy syndrome mimicking progressive multifocal leukoencephalopathy. Mult Scler (2012) 0.77
TennCare myths and realities: are we spending too much on TennCare? Tenn Med (2003) 0.77
Treatment failure of intrathecal baclofen and supra-additive effect of nabiximols in multiple sclerosis-related spasticity: a case report. Ther Adv Neurol Disord (2013) 0.76
Cost burden of the presenteeism health outcome: diverse workforce of nurses and pharmacists. J Occup Environ Med (2011) 0.76
Radiotherapy compliance is maintained with hypofractionation and concurrent cetuximab in locally advanced head and neck cancer. Radiother Oncol (2009) 0.76
Fulminant tumefactive multiple sclerosis: therapeutic implications of histopathology. J Neurol (2008) 0.75
Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. Neurology (2012) 0.75
In reply. Oral Surg Oral Med Oral Pathol Oral Radiol (2013) 0.75
Therapeutic monitoring of immunotherapies in autoimmune diseases. Curr Pharm Des (2012) 0.75
A pregnant woman with headaches, seizures, and hypertension. Lancet (2005) 0.75
TennCare myths and realities: can we cut costs without harming people? Tenn Med (2003) 0.75
Stability of Cohen-Grossberg neural networks with time-varying delays. Neural Netw (2007) 0.75
The economics of prevention: does it save money? Tenn Med (2004) 0.75
Covering the Cover. Gastroenterology (2017) 0.75
Variations in costs for the care of low-birth-weight infants among academic hospitals. Clin Pediatr (Phila) (2009) 0.75
Unusual dyspnea in a woman with CREST syndrome. Chest (2008) 0.75
Comparison of the political contributions of pharmacists with other health care professionals. Am J Health Syst Pharm (2003) 0.75
No association between genetic polymorphism at codon 129 of the prion protein gene and primary progressive multiple sclerosis. Arch Neurol (2011) 0.75
Insurance impact on nonurgent and primary care-sensitive emergency department use. Am J Manag Care (2015) 0.75
A cost-effectiveness analysis of subcutaneous interferon beta-1a 44mcg 3-times a week vs no treatment for patients with clinically isolated syndrome in Sweden. J Med Econ (2013) 0.75
Monitoring peripheral blood CD4(+) intracellular adenosine triphosphate concentration in patients with psoriasis treated with fumaric acid esters. Acta Derm Venereol (2012) 0.75
OTC Secondary Prevention of Metastatic Colorectal Cancer Moves Closer to Clinical Reality. Oncology (Williston Park) (2015) 0.75
Anti-JC-virus antibody prevalence in a German MS cohort. Mult Scler (2012) 0.75
Evaluating group purchasing organizations. Healthc Financ Manage (2003) 0.75